Diabetes, metabolic disease, and telomere length.

Diabetes Complications / genetics Diabetes Mellitus / genetics Humans Metabolic Diseases / genetics Risk Factors Telomere / genetics

Journal

The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821

Informations de publication

Date de publication:
02 2021
Historique:
received: 04 07 2020
revised: 01 10 2020
accepted: 08 10 2020
pubmed: 30 11 2020
medline: 16 2 2021
entrez: 29 11 2020
Statut: ppublish

Résumé

Telomeres are regions of repetitive nucleotide sequences at the ends of chromosomes. Telomere length is a marker of DNA damage, which is often considered a biomarker for biological ageing, and has also been linked with cardiovascular disease, diabetes, and cancer. Emerging studies have highlighted the role of genetic and environmental factors, and explored the effect of modulating telomere length. We provide an overview of studies to date on diabetes and telomere length, and compare different methods and assays for evaluating telomere length and telomerase activity. We highlight the limitations of current studies and areas that warrant further research to unravel the link between diabetes and telomere length. The value of adding telomere length to clinical risk factors to improve risk prediction of diabetes and related complications also merits further investigation.

Identifiants

DOI: 10.1016/S2213-8587(20)30365-X PMID: 33248477
pubmed: 33248477
pii: S2213-8587(20)30365-X
doi: 10.1016/S2213-8587(20)30365-X
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-126

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Feifei Cheng (F)

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory for Molecular Epidemiology in Diabetes, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.

Luke Carroll (L)

NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, Australia.

Mugdha V Joglekar (MV)

NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.

Andrzej S Januszewski (AS)

NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, Australia.

Kwun Kiu Wong (KK)

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory for Molecular Epidemiology in Diabetes, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.

Anandwardhan A Hardikar (AA)

NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Campbelltown, NSW, Australia. Electronic address: a.hardikar@westernsydney.edu.au.

Alicia J Jenkins (AJ)

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, Australia. Electronic address: alicia.jenkins@ctc.usyd.edu.au.

Ronald C W Ma (RCW)

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory for Molecular Epidemiology in Diabetes, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; Chinese University of Hong Kong-Shanghai Jiao Tong University Joint Research Centre in Diabetes Genomics and Precision Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, Australia. Electronic address: rcwma@cuhk.edu.hk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies endocriniennes › Diabète › Complications du diabète › Diabetes, metabolic disease, and telomere length.
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabetes, metabolic disease, and telomere length.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Diabetes, metabolic disease, and telomere length.
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Diabetes, metabolic disease, and telomere length.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Diabetes, metabolic disease, and telomere length.
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Structures de chromosome › Télomère › Diabetes, metabolic disease, and telomere length.